Keywords: Tumors (Pre-Treatment), Spectroscopy
Motivation: 2HG is a biomarker of IDH-mutation status in brain gliomas and could benefit the clinic but lack of accessible acquisition and analysis approaches hamper adoption.
Goal(s): Our goal was to remove barriers to 2GH-MRS in clinical workflow through use of available sequences, feasible scan time and in-line analysis methods.
Approach: Fully blinded analysis of clinically achievable MRI spectroscopy (PRESS 97ms) data using non-clinical and vendor software was compared with histopathologic IDH status.
Results: Approach was feasible and yielded similar accuracy to previously reported edited-MRS methods. Both analyses showed acceptable ROC but inline implementation was more challenging in borderline cases and some non-glial tumours.
Impact: 2HG-MRS achieved with routinely available acquisition in clinical workflow and translated to inline analysis software could promote 2HG as a usable biomarker for IDH status in practice.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords